A previously announced private placement of 4.375% senior notes due 2025 and 4.625% senior notes due 2028 was completed by Hologic, raising $1 billion. The net proceeds, along with available cash, will be used for redemption of the company's outstanding 5.25% senior notes due 2022.
An offering of equity, debt, warrants, options and other securities involving nine unnamed investors has pulled in over $132 million for Centinel Spine, a regulatory filing showed. The company recently acquired the Prodisc-C, Prodisc-L, Prodisc-C Nova, Prodisc-C Vivo, Prodisc-O and Discover cervical and lumbar artificial disc systems from Johnson & Johnson subsidiary DePuy Synthes for undisclosed terms.
An upcoming offering of 5.5 million shares was priced by weight loss balloon maker Obalon Therapeutics at $5.50 per share in hopes of raising $35 million. The offering, which includes a 30-day option for the underwriters to buy 818,181 additional shares, is expected to close on or around Tuesday, subject to satisfaction of customary closing conditions.
A previously announced public offering of 12.1 million shares of common stock was priced by HTG Molecular Diagnostics at $2.90 per share in hopes of raising $35.1 million in gross proceeds. The company, which has granted a 30-day option for the underwriters to buy up to 1.815 million additional shares, intends to use the net proceeds as working capital, as well as to support its general corporate functions.
Avon Products CEO Sheri McCoy and Nokia President and CEO Rajeev Suri have been nominated by Stryker to serve on its board of directors. The board is expected to hold a vote on the nominations on May 2.
An Envision Inteligence report predicts the worldwide market for spinal fusion devices will reach almost $17.3 billion by 2024 with a 5.3% compound annual growth rate because of a rising number of back pain and obesity cases. Among the key market players are K2M, DePuy Synthes, Medtronic, NuVasive, Orthofix and Globus Medical.
Amgen and Allergan's Mvasi, a biosimilar of Roche Holding's Avastin, was approved by the European Commission as a treatment for patients with certain types of cancer. The biosimilar is the first referencing Avastin to be approved in Europe.
AstraZeneca's Lynparza, or olaparib, received approval from the Japanese Ministry of Health, Labor and Welfare as a maintenance treatment for platinum-sensitive relapsed ovarian cancer in patients who responded to platinum-based chemotherapy. The ministry also approved the company's IL-5 inhibitor Fasenra, or benralizumab, as an add-on bronchial asthma treatment.
A study in the journal Proceedings of the National Academy of Sciences found the incidence of HIV in the Ukraine has risen by 15% to 54%, particularly in areas affected by military conflict. About half of people with HIV are unaware of their status, researcher Tetyana Vasylyeva said.